drugset / Trial / NCT00258934

Immunogenicity Study of the Influenza Vaccine in Adults

NCT00258934

Phase 2 Completed 978 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupOpen-labelPrevention

Summary

All marketed influenza vaccines are injected by the intramuscular (IM) route. This study will test whether an influenza vaccine is effective when injected by a route other than into the muscle. In order to prove this, the amount of antibodies in the blood will be measured before and after vaccination. In addition, the safety of both influenza vaccines will be tested by evaluating all serious reactions occurring after vaccination. The vaccine injected in this study is similar to the sponsor's marketed intramuscular influenza vaccine (Vaxigrip). In addition, the safety of both influenza vaccines administered by different routes will be tested by evaluating all adverse events and especially all serious reactions. Primary Objective: To demonstrate and compare the immune response of an influenza vaccine after a single dose when administered by different routes. Secondary Objectives: To describe the compliance of the immunogenicity of the vaccine with the European Medicine Agency (EMEA) after the first injection.

Timeline

Start
2005-09
Primary completion
2008-06
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Inactivated, Split-Virion Influenza Virus Vaccine 0.5 ml Intramuscular
Subject Influenza Virus Vaccine Vaccine 0.1 ml

Indications